Liraglutide
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Liraglutide: From Type 2 Diabetes Mellitus to Opsismodysplasia
One-Sentence Summary
Liraglutide is a GLP-1 receptor agonist injection, originally used to treat type 2 diabetes mellitus. The TxGNN model predicts it may be effective for opsismodysplasia, a rare skeletal dysplasia, but no clinical trials and no publications currently support this prediction. The high score is a model output only.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Type 2 diabetes mellitus (from the knowledge-graph indication record; the registration entries list no indication text) |
| Predicted New Indication | Opsismodysplasia |
| TxGNN Prediction Score | 96.12% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 2 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, liraglutide is a GLP-1 receptor agonist whose efficacy in type 2 diabetes has been established.
Opsismodysplasia is a rare skeletal dysplasia caused by mutations in INPPL1 (SHIP2), a gene involved in insulin and PI3K signaling. This is the only conceivable connection to a diabetes drug. Any link to GLP-1 receptor signaling is highly speculative, and no mechanistic link has been established. The high TxGNN score most likely reflects network-level associations in the knowledge graph rather than biological evidence.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN13905P | Victoza® solution for injection in pre-filled pen 6mg/ml | Injection, solution | — |
| SIN15338P | SAXENDA® solution for injection in pre-filled pen 6mg/ml | Injection, solution | — |
Both authorizations are valid single-ingredient products, and neither has been cancelled. Both are manufactured by Novo Nordisk. The data compiled for this report contain no approved-indication text for either.
Safety Considerations
- Contraindications and risk conditions (from knowledge-graph drug–disease records, not label text): hypoglycaemia, medullary thyroid carcinoma, multiple endocrine neoplasia, pancreatitis, thyroid disease, goitre, C-cell hyperplasia. Preclinical work also shows that GLP-1 receptor agonists can activate rodent thyroid C-cells, causing calcitonin release and C-cell proliferation.
- Drug Interactions: 100 interactions were identified. Those shown here are mostly moderate-level:
- Sympathomimetics and bronchodilators: phenylephrine, pseudoephedrine, epinephrine, formoterol, salbutamol
- Corticosteroids: hydrocortisone, triamcinolone
- Hormonal agents: estradiol, ethinylestradiol, levonorgestrel, desogestrel
- Antipsychotics: aripiprazole, asenapine
- Others: acetazolamide, hydrochlorothiazide, alpelisib, ethanol
- Minor-level examples: acetaminophen and topical corticosteroids
Please also refer to the package insert for full warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has no supporting trials or literature (L5, model prediction only), and the mechanistic link between GLP-1 receptor agonism and INPPL1-related skeletal dysplasia is speculative. Liraglutide is marketed in Singapore, but only for its existing indications, so there is no basis to advance this new use.
To proceed, the following is needed:
- Preclinical or mechanistic evidence connecting GLP-1 receptor signaling to SHIP2/INPPL1 biology or skeletal development
- Detailed mechanism of action data
- Package insert warnings and contraindications for a full safety review
- Any case reports or registered studies in opsismodysplasia
Note: Among the model's other predictions for liraglutide, type 1 diabetes mellitus (score 92.3%) has far stronger support, including multiple Phase 3 trials such as ADJUNCT ONE and ADJUNCT TWO. It may be a better candidate for a separate evaluation. The main concerns there are modest efficacy and the risks of hypoglycaemia, ketosis and gastrointestinal adverse events.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.